Outlook Therapeutics Inc. (NASDAQ: OTLK) said it is targeting more than $500 million in annual U.S. sales of LYTENAVA (bevacizumab-vikg) by 2030 as the company prepares to launch the ophthalmic formulation in the United States.
CEO Bob Jahr discussed the company’s commercial strategy in a September 10 interview, outlining plans to shift existing off-label bevacizumab use over to LYTENAVA, the only FDA-approved ophthalmic formulation of the drug in the U.S.
LYTENAVA is a recombinant humanized IgG1 monoclonal antibody that binds to vascular endothelial growth factor (VEGF), inhibiting processes that contribute to vision loss in patients with wet age-related macular degeneration (wet AMD). The most common adverse reactions reported in clinical trials include conjunctival hemorrhage, eye pain, and vitreous floaters.
The U.S. commercial launch is planned before the end of 2026. Commercial readiness efforts are underway across manufacturing, distribution, market access, reimbursement, and physician education, Jahr said. The company is also drawing on prior commercialization experience from Europe, where LYTENAVA has already received Marketing Authorization from the European Commission and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Commercial launches have commenced in Germany, Austria, and the UK.
Shares of Outlook Therapeutics closed at $0.653 on the day of the interview, down $0.028 or 4.11%. In after-hours trading, the stock rose to $0.678, up $0.025 or 3.86%.
The company is headquartered in Iselin, New Jersey.
